TELIX PHARMACEUTICALS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.05 AUD | -2.97% |
|
+5.24% | +49.31% |
| 03:36am | Bell Potter Downgrades Telix Pharmaceuticals to Hold from Buy, Price Target is AU$14.50 | MT |
| 04-18 | Jarden Adjusts Telix Pharmaceuticals Price Target to AU$13.52 from AU$13.27, Keeps at Buy | MT |
Chart calendar Telix Pharmaceuticals Limited
8904849c470c1b69768ad19eb0e99.PMNe-jzx9JpTg20HIEnToKHHwZCGoegh4BOafk7wdAg.bZMLlEqZkKoJ8jJASwC97JKmhvS1xakYkUnYLwKIA1hTrHOpaImZ7DTvXQ~ac1981f10f90f65a1f1854e3e7271d0c
Upcoming events on Telix Pharmaceuticals Limited
Past events on Telix Pharmaceuticals Limited
| 2024-04-17 02:07 | March 2024 Sales and Revenue Release - Activities Report |
| 2024-04-04 19:00 | Shareholders Meeting |
| 2024-03-04 | ASX CEO Connect Meeting |
| 2024-02-22 17:00 | Q4 2023 Earnings Call |
| 2024-02-22 04:22 | Q4 2023 Earnings Release |
| 2024-01-09 18:00 | JPMorgan Healthcare Conference |
| 2023-12-05 | San Antonio Breast Cancer Symposium |
| 2023-11-20 18:15 | Investor Meeting - Key Opinion Leader |
| 2023-11-15 11:00 | Jefferies London Healthcare Conference |
| 2023-10-18 17:30 | September 2023 Sales and Revenue Call - Activities Report |
| 2023-10-18 03:37 | September 2023 Sales and Revenue Release - Activities Report |
| 2023-08-23 18:30 | Q2 2023 Earnings Call |
| 2023-08-23 04:44 | Q2 2023 Earnings Release |
| 2023-07-19 18:30 | June 2023 Sales and Revenue Call - Activities Report |
| 2023-07-19 04:14 | June 2023 Sales and Revenue Release - Activities Report |
| 2023-06-26 12:15 | Society of Nuclear Medicine and Molecular Imaging Meeting - Abstract No : P1178 |
| 2023-06-26 12:15 | Society of Nuclear Medicine and Molecular Imaging Meeting - Abstract No : P968 |
| 2023-06-26 12:15 | Society of Nuclear Medicine and Molecular Imaging Meeting - Abstract No.: P1408 |
| 2023-06-26 12:05 | Society of Nuclear Medicine and Molecular Imaging Meeting - Abstract No : P1271 |
| 2023-06-26 11:55 | Society of Nuclear Medicine and Molecular Imaging Meeting - Abstract No : P1113 |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million AUD | Released Forecast Spread | 3,49 5,09 -31.59% | 5,21 23,4 -77.76% | 7,60 8,19 -7.29% | 160 156 2.39% | 503 501 0.34% | 741 |
|
EBITDA Million AUD | Released Forecast Spread | -24,5 -16,1 -52.1% | -34,6 -7,04 -391.43% | -70,1 -48,5 -44.42% | -67,8 -69,5 2.43% | 58,4 63,8 -8.48% | 98,0 |
|
EBIT Million AUD | Released Forecast Spread | -28,7 -19,5 -47.34% | -39,5 -14,7 -167.64% | -75,2 -56,5 -33.09% | -73,2 -75,0 2.43% | 51,7 46,1 12.25% | 85,5 |
|
Earnings before Tax (EBT) Million AUD | Released Forecast Spread | -31,1 -24,6 -26.62% | -47,9 -19,9 -141.05% | -80,5 -50,5 -59.34% | -98,6 -74,7 -31.95% | 3,09 28,9 -89.31% | 68,3 |
|
Net income Million AUD | Released Forecast Spread | -27,9 -17,9 -55.7% | -44,9 -12,4 -262.21% | -80,5 -50,9 -58.1% | -104 -79,7 -30.63% | 5,21 8,78 -40.65% | 43,2 |
|
EPS AUD | Released Forecast Spread | -0,12 -0,08 -53.04% | -0,17 -0,05 -282.01% | -0,29 -0,18 -56.34% | -0,34 -0,25 -36.73% | 0,02 0,04 -59.17% | 0,14 |
| Announcement Date | 23/02/20 | 25/02/21 | 23/02/22 | 27/02/23 | 22/02/24 | - |
Quarterly results
| Fiscal Period | December | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2022 S2 | 2023 Q2 | 2023 S1 | 2023 S2 | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 Q4 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million AUD | Released Forecast Spread | 1,61 | 2,91 2,50 16.4% | 4,69 4,00 17.15% | 24,0 21,2 13.43% | 55,3 | 80,7 68,9 17.28% | 136 128 6.26% | 121 120 0.58% | 221 220 0.56% | 282 278 1.3% | 178 | 353 | 178 | 181 | 359 | |
|
EBITDA Million AUD | Released Forecast Spread | -23,6 18,7 -226.01% | -27,4 -23,0 -19.12% | -7,05 -13,6 48.19% | 34,7 33,9 2.58% | 23,7 48,6 -51.16% | |||||||||||
|
EBIT Million AUD | Released Forecast Spread | -29,9 -27,1 -10.49% | -45,3 -25,7 -76.28% | -63,5 -27,1 -134.23% | -9,70 -10,1 3.92% | 31,5 27,7 14.03% | 20,2 53,5 -62.31% | -6,20 | |||||||||
|
Earnings before Tax (EBT) Million AUD | Released Forecast Spread | -28,7 2,80 -1124.61% | -32,4 -27,0 -20.18% | -70,7 -27,9 -153.42% | |||||||||||||
|
Net income Million AUD | Released Forecast Spread | -26,6 2,70 -1084.67% | -32,5 -27,0 -20.42% | -70,9 -27,9 -154.09% | -33,2 -25,2 -31.7% | 19,5 16,7 16.95% | |||||||||||
|
EPS AUD | Released Forecast Spread | -0,07 | -0,10 0,00 - | -0,12 -0,09 -29.89% | -0,23 -0,09 -159.21% | ||||||||||||
| Announcement Date | 20/08/20 | 25/02/21 | 18/08/21 | 23/02/22 | 17/08/22 | 19/10/22 | 27/02/23 | 27/02/23 | 23/08/23 | 23/08/23 | 22/02/24 | - | - | - | - | - |
More events
Past sector events for Telix Pharmaceuticals Limited
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- TLX Stock
- Calendar Telix Pharmaceuticals Limited
